TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology today announced the presentation of a poster containing data on a new DRP for the monoclonal antibody drug daratumumab. The post ...

GRAND CAYMAN, Cayman Islands, April 25, 2025 (GLOBE NEWSWIRE) -- Oxbridge Re Holdings Limited (Nasdaq: OXBR) (“Oxbridge Re”), together with its subsidiary SurancePlus, is engaged in the tokenization of Real-World Assets (“RWAs”), initially with tokenized reinsurance securities and in providing reinsurance solutions to property and casualty insurers in the Gulf Coast region of the United States. The company today announced its participation in TOKEN2049 Dubai, one of the world’s premier blockchain events, ta ...

CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 082088. A webcast of the call will also be available under "Events and Presentations" in th ...

文章核心观点 公司宣布因任命Eric Poma博士为首席执行官，薪酬委员会和董事会批准授予其非合格股票期权 [1] 公司动态 - 公司薪酬委员会和董事会批准授予Eric Poma博士非合格股票期权，可购买726,412股，行权价为0.469美元，授予日期为2025年4月22日 [1] - 股票期权分四年归属，25%在授予日一周年（2026年4月22日）归属，其余按月等额归属直至2029年4月22日，受股票期权协议条款约束 [2] 公司介绍 - 公司是临床阶段免疫肿瘤公司，拥有专有技术，利用异体干细胞携带溶瘤病毒用于多种肿瘤适应症，包括高级别胶质瘤和实体瘤 [3] - 临床阶段即用型通用细胞递送平台可保护、扩增和增强溶瘤病毒，提高疗效和患者安全性，临床前即用型包膜病毒疗法可靶向播散性实体瘤，双管齐下可治疗或预防转移性疾病 [3] 公司联系方式 - 公司企业传播联系人为Dave Gentry，来自RedChip Companies, Inc.，联系电话1 - 407 - 644 - 4256，邮箱CLDI@redchip.com [5]

SINGAPORE, April 25, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading AI-powered, Bitcoin-first education group, will announce full year 2024 financial results on Wednesday, April 30, 2025, prior to market open. Management will host a live webcast to discuss the results at 8:00 AM Eastern Time / 8:00 PM Singapore Time on Wednesday, April 30, 2025. Management will also provide updates on its AI-Powered Genius Curriculum, Genius City model, Bitcoi ...

Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tumor cell death, and the mechanisms underlying its superior potency observed preclinically Phase 1 trial of ACR-2316 ahead of schedule with three dose-escalation cohorts completed; solid tumor shrinkage already observed at dose level three, well below the projected recommended Phase 2 dose WATERTOWN, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “A ...

CHICAGO, April 25, 2025 /PRNewswire/ -- Telephone and Data Systems, Inc. (NYSE: TDS) and United States Cellular Corporation (NYSE: USM) will be webcasting their first quarter operating results conference call on May 2, 2025, at 9:00 a.m. Central Time. The companies will release their financial results on May 2, 2025. To listen to the webcast, please visit the events & presentations pages of investors.tdsinc.com or investors.uscellular.com. The presentations will be webcast both live and on-demand. It is rec ...

SANTA CLARA, Calif., April 25, 2025 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to assist its customers in evaluating and treating chronic diseases, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, as well as its at-the-market equity offering (ATM) programs. BTC Update Between February 14, 2025 and April 24, 2025, Semler Scientific acquired 111 bitcoins for $10.0 million with an average purcha ...

BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the Company that it placed a clinical hold on the Company’s Phase 1b study evaluating VYN202 for the treatment of moderate-to-severe plaque psoriasis. The clinical hold determination was made following a recent observation of testicular toxicity in dogs from a non-clinical toxicology study with VYN202. VYNE ha ...

ACHESON, Alberta, April 25, 2025 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG”) (TSX: NOA / NYSE: NOA) announced today that it has entered into an underwriting agreement to sell, pursuant to a private placement offering (the “Offering”), $225 million aggregate principal amount of 7.75% Senior Unsecured Notes due May 1, 2030 (the “Notes”). The Notes will be issued at a price of $1,000 per $1,000 of Notes. The Notes will accrue interest at the rate of 7.75% per annum, payable in cash in e ...